OBSIDIAN THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
OBSIDIAN THERAPEUTICS, INC. (OBX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.55 million for the 3-month period ending 2026-06-30, per its S-1 filed 2026-08-28.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-28
- OBSIDIAN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.55M, a 43.79% decline year-over-year.
- OBSIDIAN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.45M, a 31.09% decline year-over-year.
- OBSIDIAN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.76M.
- OBSIDIAN THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $2.11M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|
| 2026-06-30 | $1.55M S-1 · filed 2026-08-28 | $3.01M derived: sum of 2 quarters · filed 2026-08-28 | |
| 2026-03-31 | $1.45M S-1 · filed 2026-08-28 | ||
| 2025-12-31 | $8.93M S-1 · filed 2026-08-28 | ||
| 2025-06-30 | $2.76M S-1 · filed 2026-08-28 | $4.87M derived: sum of 2 quarters · filed 2026-08-28 | |
| 2025-03-31 | $2.11M S-1 · filed 2026-08-28 | ||
| 2024-12-31 | $7.06M S-1 · filed 2026-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |